Registration Options

Activity Dates: 04/26/2022 - 04/26/2025

Session Time and Location

The live session is complete.

Target Audience

If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.

Session Summary

Tourette’s Disorder (TD) is a chronic neurological disorder with age of onset prior to 18 years. The hallmark symptoms are repetitive, stereotyped movements and vocalizations called tics that wax and wane. The overall prevalence of TD in children has been reported at 7.7 per 1000 school-aged children. Tics initially present between the ages of 8 and 12 years, followed by a gradual decrease throughout adolescent and young adulthood. Approximately 20% of patients do not experience a decrease in tics and some of these patients might also go on to develop the most severe and debilitating forms of complex tics. There is currently no cure while symptomatic FDA-approved or off-label treatment is available; additionally, there are some potential new pharmacological treatments under investigation. However, there is no treatment that has proven efficacious for symptom suppression in all individuals with TD, likely due to phenotypic variabilities. Different psychiatric comorbidities are common and treatment strategies must take into consideration comorbidity-related treatment goals. This program will provide the most up-to-date information regarding clinical presentation, diagnosis, and treatment options and challenges for TD with or without comorbid OCD and ADHD in order to provide competent patient-centered care grounded in evidence for individuals with TD.

Course Requirements

To receive ACPE credit for this session, you must:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.
Upon successful completion, ACPE credit is reported within 24 hours to CPE Monitor although transcripts can be retrieved by participants online in their ACPE Transcript.

Faculty Information

Sandra Mullen, PharmD, BCPP

View biographical information

Learning Objectives

  1. Review recent updates on genomics and clinical phenomenology of Tourette’s Disorder (TD).
  2. Discuss the efficacy and safety of available behavioral and pharmacologic treatment modalities and their place in therapy.
  3. Describe considerations for TD management in the presence of psychiatric comorbidities including attention-deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD).
  4. Identify a pharmacotherapy treatment plan for an individual with TD.

Continuing Education Credit and Disclosures

Activity Dates: 04/26/2022 - 04/26/2025
ACPE Contact Hours: 1
ACPE Number: 0284-0000-22-051-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for ANCC Certification Renewal and AANPCB advanced practice provider content. For specific questions related to your organization's acceptance of ACPE continuing education units, please contact your organization directly.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.